BMS-903452 NEW
| Price | $154 | $385 | $547 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: BMS-903452 | CAS No.: 1339944-47-6 |
| Purity: 100% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | BMS-903452 |
| Description | BMS-903452 is a potent and selective GPR119 agonist with an EC50 of 14 nM, indicated for the treatment of acute and chronic rodent diabetes. GPR119 is mainly expressed in pancreatic b cells and gastrointestinal endocrine cells. BMS-903452 shows no significant inhibitory effect on 9 cytochrome P450 enzymes (IC50 > 40 μM), does not activate PXR (EC50 > 50 μM), and is not toxic to liver (HEPG2) cell lines. |
| In vivo | An oral glucose tolerance test (OGTT) to measure the acute efficacy of this agonist in C57/BL6 mice. Glucose excursion was 37%-40% lower in mice treated with BMS-903452 (0.1, 0.3, and 1 mg/kg) than in control mice. Treatment of SD rats with 0.3 mg/kg BMS-903452 stimulated GLP-1 production, and co-administration of BMS-903452 with a DPP-4 inhibitor synergistically augmented GLP-1 levels. [1] BMS-903452 (0.03 mg/kg/day) also reduced fasting plasma glucose levels with increased insulin levels in db/db mice. [1] BMS-903452 was safe and tolerable in normal healthy volunteers given a single dose ranging from 0.1 to 120mg, but did not alter plasma GLP-1 within the first 24 h of treatment.[2] |
| Storage | Shipping with blue ice. |
| Solubility Information | DMSO : 10 mg/mL (19.48 mM) |
| Inhibitors Related | Vincamine | Monomethyl fumarate | Questiomycin A | 3-Hydroxyoctanoic Acid | CRTh2 antagonist 2 | Fezagepras sodium | Benzyl nicotinate | 1-methoxycyclopropanecarboxylic acid | TUG-1375 | CAY10595 | Timapiprant | NF-56-EJ40 |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1g |
VIP2Y
|
shandong perfect biotechnology co.ltd
|
2023-08-14 | |
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-12-30 | |
| $0.00/1KG |
VIP3Y
|
Wuhan Senwayer Century Chemical Co.,Ltd
|
2023-02-17 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY